{
    "clinical_study": {
        "@rank": "166524", 
        "arm_group": {
            "arm_group_label": "WaveLight\u00ae Refractive Suite", 
            "arm_group_type": "Experimental", 
            "description": "LASIK surgery (laser in situ keratomileusis) per standard care of treatment and medication"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate outcomes of subjects undergoing myopic treatments\n      using the WaveLight\u00ae Refractive Suite (Excimer EX500 and Femtosecond FS200 laser)."
        }, 
        "brief_title": "WaveLight\u00ae Refractive Myopic Study", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Refractive Error", 
        "condition_browse": {
            "mesh_term": "Refractive Errors"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Willing and able to understand and sign an informed consent form.\n\n          -  Have refractive error (in both eyes) that requires refractive surgery.\n\n          -  Willing to undergo LASIK surgery using the Wavelight\u00ae Refractive Suite.\n\n          -  Myopia between 0.00 to -12.0 diopters pre-operatively.\n\n          -  Astigmatism between 0.00 to +6.00 diopters pre-operatively.\n\n          -  Willing and able to attend post-operative examinations per protocol schedule.\n\n          -  Other protocol-defined inclusion criteria may apply.\n\n        Exclusion Criteria:\n\n          -  Participation in a clinical study within the last 30 days.\n\n          -  History of previous corneal surgery in either eye.\n\n          -  Multifocal ablations in either eye.\n\n          -  PRK or PTK surgery in either eye.\n\n          -  Suffering from acute or recurring eye diseases in either eye, such as corneal ulcers,\n             cataract, etc.\n\n          -  Any ocular disease and/or condition that, in the Investigator's clinical judgment,\n             may put subject at significant risk, compromise study results, or interfere\n             significantly with subject's participation in the study.\n\n          -  Unable to discontinue contact lens wear as specified in protocol.\n\n          -  History of Herpes simplex or Herpes zoster keratitis.\n\n          -  Active ocular rosacea.\n\n          -  Lyme disease.\n\n          -  History of dry eye that is unresponsive to treatment.\n\n          -  Severe ocular allergies.\n\n          -  Other medical conditions and use of medications as specified in protocol.\n\n          -  Pregnant or planning to become pregnant during the study.\n\n          -  Other protocol-specified exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01941498", 
            "org_study_id": "A01353"
        }, 
        "intervention": [
            {
                "arm_group_label": "WaveLight\u00ae Refractive Suite", 
                "description": "Excimer EX500 and Femtosecond FS200 lasers (Wavelight\u00ae Refractive Suite) used during LASIK surgery for corneal flap creation and corneal ablation", 
                "intervention_name": "Wavelight\u00ae Refractive Suite", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "WaveLight\u00ae Refractive Suite", 
                "description": "Surgical procedure for treating refractive error based on corneal reshaping", 
                "intervention_name": "LASIK surgery", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "nearsighted", 
            "farsighted", 
            "astigmatism", 
            "LASIK", 
            "refractive surgery", 
            "WaveLight"
        ], 
        "lastchanged_date": "February 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fort Worth", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "76134"
                }, 
                "name": "Contact Alcon Call Center for Trial Locations"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Prospective, Global, Multi-Center Study for the Evaluation of Outcomes on Subjects Undergoing Myopic Treatments Using the WaveLight\u00ae Refractive Suite", 
        "overall_official": {
            "affiliation": "Alcon Research", 
            "last_name": "Stefani Smith, MS", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "Ireland: Research Ethics Committee", 
                "Germany: Ethics Commission"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "UCVA (ie, without spectacles) will be performed at a distance of four meters. UCVA is measured in logMAR (minimum angle of resolution), with a lower logMAR indicating better visual acuity.", 
            "measure": "Uncorrected visual acuity (UCVA)", 
            "safety_issue": "No", 
            "time_frame": "Month 1"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01941498"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The thickness of the corneal flap will be assessed by OCT (ie, an imaging method using light to capture three-dimensional images). Corneal flap thickness is measured in microns.", 
                "measure": "Corneal flap thickness as assessed by ocular coherence tomography (OCT)", 
                "safety_issue": "No", 
                "time_frame": "Up to Month 6"
            }, 
            {
                "description": "A series of test lenses in graded powers will be used to determine which corrective lenses provide the sharpest, clearest vision. Manifest refraction is measured in diopters.", 
                "measure": "Manifest refraction per standard of care", 
                "safety_issue": "No", 
                "time_frame": "Up to Month 6"
            }, 
            {
                "description": "Total treatment time with Excimer EX500 and Femtosecond FS200 lasers will be measured in seconds and minutes.", 
                "measure": "Total treatment time as documented in the log files", 
                "safety_issue": "No", 
                "time_frame": "Day 0 (surgery)"
            }, 
            {
                "description": "The Refractive Status and Vision Profile (RSVP) Questionnaire measures self-reported vision-related health status in persons with refractive error.", 
                "measure": "Spectacle independence as reported on the RSVP Questionnaire for Quality of Life and Retreatment", 
                "safety_issue": "No", 
                "time_frame": "Up to Month 6"
            }, 
            {
                "description": "Contrast acuity (ie, a measurement of the ability to see between different shades of gray from the background) will be assessed in accordance with the manufacturer's guidelines. Contrast acuity is measured in logMAR, with a lower logMAR indicating better contrast acuity.", 
                "measure": "Contrast Acuity", 
                "safety_issue": "No", 
                "time_frame": "Up to Month 6"
            }, 
            {
                "description": "Wavefront aberrometry measures the eye's image-forming quality and optical abnormalities and how visual acuity is affected. Total RMS (ie, the overall magnitude of all the eye's refractive errors) will be assessed using a commercially available system. Total RMS is measured in 0.01 microns.", 
                "measure": "Total root square mean (RMS) as determined by wavefront aberrometry", 
                "safety_issue": "No", 
                "time_frame": "Up to Month 6"
            }, 
            {
                "description": "Corneal curvature will be assessed using a commercially available system. Corneal curvature is measured in diopters.", 
                "measure": "Corneal curvature as measured by keratometry", 
                "safety_issue": "No", 
                "time_frame": "Up to Month 6"
            }, 
            {
                "description": "Wavefront aberrometry measures the eye's image-forming quality and optical abnormalities and how visual acuity is affected. WFO profile will be assessed using a commercially available system.", 
                "measure": "Wavefront optimization profile (WFO) as determined by wavefront aberrometry", 
                "safety_issue": "No", 
                "time_frame": "Up to Month 6"
            }
        ], 
        "source": "Alcon Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alcon Research", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}